版本:
中国

BRIEF-Epizyme announces fast track designation for Tazemetostat in DLBCL

Nov 28 Epizyme Inc :

* Epizyme announces fast track designation for tazemetostat in DLBCL and provides solid tumor program update

* Epizyme announces fast track designation for tazemetostat in dlbcl and provides solid tumor program update

* Epizyme inc - Epizyme plans to present data from phase 2 trial in first half of 2017

* Fda granted Tazemetostat fast track designation in patients with diffuse large b-cell lymphoma with EZH2 activating mutations Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐